Thomas N. Chase, M.D. - Publications

Affiliations: 
National Institutes of Health, Bethesda, MD 
Area:
Parkinson's disease

247 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any innacuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2008 Vanover KE, Betz AJ, Weber SM, Bibbiani F, Kielaite A, Weiner DM, Davis RE, Chase TN, Salamone JD. A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model. Pharmacology, Biochemistry, and Behavior. 90: 540-4. PMID 18534670 DOI: 10.1016/j.pbb.2008.04.010  0.8
2007 Liang ZQ, Wang X, Li LY, Wang Y, Chen RW, Chuang DM, Chase TN, Qin ZH. Nuclear factor-kappaB-dependent cyclin D1 induction and DNA replication associated with N-methyl-D-aspartate receptor-mediated apoptosis in rat striatum. Journal of Neuroscience Research. 85: 1295-309. PMID 17385714 DOI: 10.1002/jnr.21248  1
2007 Liang ZQ, Li YL, Zhao XL, Han R, Wang XX, Wang Y, Chase TN, Bennett MC, Qin ZH. NF-kappaB contributes to 6-hydroxydopamine-induced apoptosis of nigral dopaminergic neurons through p53. Brain Research. 1145: 190-203. PMID 17368433 DOI: 10.1016/j.brainres.2007.01.130  1
2007 Smith CP, Oh JD, Bibbiani F, Collins MA, Avila I, Chase TN. Tamoxifen effect on L-DOPA induced response complications in parkinsonian rats and primates. Neuropharmacology. 52: 515-26. PMID 17116309 DOI: 10.1016/j.neuropharm.2006.08.018  1
2006 Bara-Jimenez W, Dimitrova TD, Sherzai A, Aksu M, Chase TN. Glutamate release inhibition ineffective in levodopa-induced motor complications. Movement Disorders : Official Journal of the Movement Disorder Society. 21: 1380-3. PMID 16758479 DOI: 10.1002/mds.20976  1
2006 Andringa G, Bol JG, Wang X, Boekel A, Bennett MC, Chase TN, Drukarch B. Changed distribution pattern of the constitutive rather than the inducible HSP70 chaperone in neuromelanin-containing neurones of the Parkinsonian midbrain. Neuropathology and Applied Neurobiology. 32: 157-69. PMID 16599944 DOI: 10.1111/j.1365-2990.2006.00714.x  1
2005 Bibbiani F, Oh JD, Kielaite A, Collins MA, Smith C, Chase TN. Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD. Experimental Neurology. 196: 422-9. PMID 16203001 DOI: 10.1016/j.expneurol.2005.08.017  1
2005 Liang ZQ, Wang XX, Wang Y, Chuang DM, DiFiglia M, Chase TN, Qin ZH. Susceptibility of striatal neurons to excitotoxic injury correlates with basal levels of Bcl-2 and the induction of P53 and c-Myc immunoreactivity. Neurobiology of Disease. 20: 562-73. PMID 15922606 DOI: 10.1016/j.nbd.2005.04.011  1
2005 Bara-Jimenez W, Bibbiani F, Morris MJ, Dimitrova T, Sherzai A, Mouradian MM, Chase TN. Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 20: 932-6. PMID 15791634 DOI: 10.1002/mds.20370  1
2005 Zhang HL, Huang ZH, Zhu Y, Liang ZQ, Han R, Wang XX, Chase TN, Qin ZH. Neuroprotective effects of prostaglandin A1 in animal models of focal ischemia. Brain Research. 1039: 203-6. PMID 15781063 DOI: 10.1016/j.brainres.2005.01.046  1
2005 Bibbiani F, Costantini LC, Patel R, Chase TN. Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates. Experimental Neurology. 192: 73-8. PMID 15698620 DOI: 10.1016/j.expneurol.2004.11.013  1
2005 Chase TN. Pathogenesis of motor complications Principles of Treatment in Parkinson's Disease. 67-98. DOI: 10.1016/B978-0-7506-5428-9.50008-1  1
2004 Bara-Jimenez W, Dimitrova T, Sherzai A, Favit A, Mouradian MM, Chase TN. Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 19: 1183-6. PMID 15390018 DOI: 10.1002/mds.20124  1
2004 Wessell RH, Ahmed SM, Menniti FS, Dunbar GL, Chase TN, Oh JD. NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats. Neuropharmacology. 47: 184-94. PMID 15223297 DOI: 10.1016/j.neuropharm.2004.03.011  1
2004 Chase TN. Striatal plasticity and extrapyramidal motor dysfunction. Parkinsonism & Related Disorders. 10: 305-13. PMID 15196510 DOI: 10.1016/j.parkreldis.2004.02.012  1
2004 Andringa G, Lam KY, Chegary M, Wang X, Chase TN, Bennett MC. Tissue transglutaminase catalyzes the formation of alpha-synuclein crosslinks in Parkinson's disease. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 18: 932-4. PMID 15001552 DOI: 10.1096/fj.03-0829fje  1
2003 Chase TN, Bibbiani F, Bara-Jimenez W, Dimitrova T, Oh-Lee JD. Translating A2A antagonist KW6002 from animal models to parkinsonian patients. Neurology. 61: S107-11. PMID 14663022  1
2003 Bibbiani F, Oh JD, Petzer JP, Castagnoli N, Chen JF, Schwarzschild MA, Chase TN. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Experimental Neurology. 184: 285-94. PMID 14637099 DOI: 10.1016/S0014-4886(03)00250-4  1
2003 Andringa G, Du F, Chase TN, Bennett MC. Mapping of rat brain using the Synuclein-1 monoclonal antibody reveals somatodendritic expression of alpha-synuclein in populations of neurons homologous to those vulnerable to Lewy body formation in human synucleopathies. Journal of Neuropathology and Experimental Neurology. 62: 1060-75. PMID 14575241  1
2003 Bara-Jimenez W, Sherzai A, Dimitrova T, Favit A, Bibbiani F, Gillespie M, Morris MJ, Mouradian MM, Chase TN. Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology. 61: 293-6. PMID 12913186  1
2003 Chase TN, Bibbiani F, Oh JD. Striatal glutamatergic mechanisms and extrapyramidal movement disorders. Neurotoxicity Research. 5: 139-46. PMID 12832228 DOI: 10.1007/BF03033378  1
2003 Blanchet PJ, Konitsiotis S, Mochizuki H, Pluta R, Emerich DF, Chase TN, Mouradian MM. Complications of a trophic xenotransplant approach in parkinsonian monkeys. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 27: 607-12. PMID 12787846 DOI: 10.1016/S0278-5846(03)00048-4  1
2003 Oh JD, Chartisathian K, Ahmed SM, Chase TN. Cyclic AMP responsive element binding protein phosphorylation and persistent expression of levodopa-induced response alterations in unilateral nigrostriatal 6-OHDA lesioned rats. Journal of Neuroscience Research. 72: 768-80. PMID 12774317 DOI: 10.1002/jnr.10629  1
2003 Oh JD, Geller AI, Zhang Gr, Chase TN. Gene transfer of constitutively active protein kinase C into striatal neurons accelerates onset of levodopa-induced motor response alterations in parkinsonian rats. Brain Research. 971: 18-30. PMID 12691833 DOI: 10.1016/S0006-8993(03)02348-5  1
2003 Blanchet PJ, Metman LV, Chase TN. Renaissance of amantadine in the treatment of Parkinson's disease. Advances in Neurology. 91: 251-7. PMID 12442683  1
2003 Schwarzschild MA, Chen JF, Chase TN. A2A antagonists for PD: A prime example of translational neuroscience Neurology. 61: S3-S4.  1
2002 Wang X, Qin ZH, Leng Y, Wang Y, Jin X, Chase TN, Bennett MC. Prostaglandin A1 inhibits rotenone-induced apoptosis in SH-SY5Y cells. Journal of Neurochemistry. 83: 1094-102. PMID 12437580 DOI: 10.1046/j.1471-4159.2002.01224.x  1
2002 Oh JD, Bibbiani F, Chase TN. Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models. Experimental Neurology. 177: 557-64. PMID 12429201 DOI: 10.1006/exnr.2002.8009  1
2002 Tessitore A, Hariri AR, Fera F, Smith WG, Chase TN, Hyde TM, Weinberger DR, Mattay VS. Dopamine modulates the response of the human amygdala: a study in Parkinson's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 22: 9099-103. PMID 12388617  1
2002 Oh JD, Chase TN. Glutamate-mediated striatal dysregulation and the pathogenesis of motor response complications in Parkinson's disease. Amino Acids. 23: 133-9. PMID 12373527 DOI: 10.1007/s00726-001-0118-2  1
2002 Verhagen Metman L, Morris MJ, Farmer C, Gillespie M, Mosby K, Wuu J, Chase TN. Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology. 59: 694-9. PMID 12221159  1
2002 Jeffries KJ, Schooler C, Schoenbach C, Herscovitch P, Chase TN, Braun AR. The functional neuroanatomy of Tourette's syndrome: an FDG PET study III: functional coupling of regional cerebral metabolic rates. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 27: 92-104. PMID 12062910 DOI: 10.1016/S0893-133X(01)00428-6  1
2002 Mattay VS, Tessitore A, Callicott JH, Bertolino A, Goldberg TE, Chase TN, Hyde TM, Weinberger DR. Dopaminergic modulation of cortical function in patients with Parkinson's disease. Annals of Neurology. 51: 156-64. PMID 11835371 DOI: 10.1002/ana.10078  1
2001 Bibbiani F, Oh JD, Chase TN. Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology. 57: 1829-34. PMID 11723272  1
2001 Chase TN, Konitsiotis S, Oh JD. Striatal molecular mechanisms and motor dysfunction in Parkinson's disease. Advances in Neurology. 86: 355-60. PMID 11553996  1
2001 Del Dotto P, Pavese N, Gambaccini G, Bernardini S, Metman LV, Chase TN, Bonuccelli U. Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study. Movement Disorders : Official Journal of the Movement Disorder Society. 16: 515-20. PMID 11391748 DOI: 10.1002/mds.1112  1
2001 Hutton JT, Metman LV, Chase TN, Juncos JL, Koller WC, Pahwa R, LeWitt PA, Samii A, Tsui JK, Calne DB, Waters CH, Calabrese VP, Bennett JP, Barrett R, Morris JL. Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease with N-0923 TDS: a double-blind, placebo-controlled study. Movement Disorders : Official Journal of the Movement Disorder Society. 16: 459-63. PMID 11391739 DOI: 10.1002/mds.1085  1
2001 Metman LV, Gillespie M, Farmer C, Bibbiani F, Konitsiotis S, Morris M, Shill H, Bara-Jimenez W, Mouradian MM, Chase TN. Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease. Clinical Neuropharmacology. 24: 163-9. PMID 11391128 DOI: 10.1097/00002826-200105000-00008  1
2001 Leng Y, Chase TN, Bennett MC. Muscarinic receptor stimulation induces translocation of an alpha-synuclein oligomer from plasma membrane to a light vesicle fraction in cytoplasm. The Journal of Biological Chemistry. 276: 28212-8. PMID 11337491 DOI: 10.1074/jbc.M011121200  1
2001 Qin ZH, Wang Y, Chen RW, Wang X, Ren M, Chuang DM, Chase TN. Prostaglandin A(1) protects striatal neurons against excitotoxic injury in rat striatum. The Journal of Pharmacology and Experimental Therapeutics. 297: 78-87. PMID 11259530  1
2000 Chase TN, Oh JD. Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends in Neurosciences. 23: S86-91. PMID 11052225  1
2000 Chase TN, Oh JD, Konitsiotis S. Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms. Journal of Neurology. 247: II36-42. PMID 10991664  1
2000 Marin C, Jimenez A, Bonastre M, Chase TN, Tolosa E. Non-NMDA receptor-mediated mechanisms are involved in levodopa-induced motor response alterations in Parkinsonian rats. Synapse (New York, N.Y.). 36: 267-74. PMID 10819904 DOI: 10.1002/(SICI)1098-2396(20000615)36:4<267::AID-SYN3>3.0.CO;2-Y  1
2000 Konitsiotis S, Blanchet PJ, Verhagen L, Lamers E, Chase TN. AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology. 54: 1589-95. PMID 10762498  1
2000 Chase TN, Oh JD. Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. Annals of Neurology. 47: S122-9; discussion S. PMID 10762139  1
2000 Nakai M, Qin Z, Wang Y, Chase TN. NMDA and non-NMDA receptor-stimulated IkappaB-alpha degradation: differential effects of the caspase-3 inhibitor DEVD.CHO, ethanol and free radical scavenger OPC-14117. Brain Research. 859: 207-16. PMID 10719066 DOI: 10.1016/S0006-8993(00)01959-4  1
2000 Nakai M, Qin ZH, Chen JF, Wang Y, Chase TN. Kainic acid-induced apoptosis in rat striatum is associated with nuclear factor-kappaB activation. Journal of Neurochemistry. 74: 647-58. PMID 10646516 DOI: 10.1046/j.1471-4159.2000.740647.x  1
2000 Oh JD, Chartisathian K, Chase TN, Butcher LL. Overexpression of neurotrophin receptor p75 contributes to the excitotoxin-induced cholinergic neuronal death in rat basal forebrain. Brain Research. 853: 174-85. PMID 10640615 DOI: 10.1016/S0006-8993(99)02054-5  1
2000 Metman LV, Konitsiotis S, Chase TN. Pathophysiology of motor response complications in Parkinson's disease: hypotheses on the why, where, and what. Movement Disorders : Official Journal of the Movement Disorder Society. 15: 3-8. PMID 10634235 DOI: 10.1002/1531-8257(200001)15:1<3::AID-MDS1003>3.0.CO;2-E  1
2000 Verhagen Metman L, Del Dotto P, LePoole K, Konitsiotis S, Fang J, Chase TN. Amantadine for levodopa-induced dyskinesias | Amantadin bei levodopa-induzierten dyskinesien: Eine 1-jahres- kontrollstudie Nervenheilkunde. 19: 276-279.  1
1999 Wang Y, Qin ZH, Nakai M, Chen RW, Chuang DM, Chase TN. Co-stimulation of cyclic-AMP-linked metabotropic glutamate receptors in rat striatum attenuates excitotoxin-induced nuclear factor-kappaB activation and apoptosis. Neuroscience. 94: 1153-62. PMID 10625054 DOI: 10.1016/S0306-4522(99)00264-X  1
1999 Agid Y, Ahlskog E, Albanese A, Calne D, Chase T, De Yebenes J, Factor S, Fahn S, Gershanik O, Goetz C, Koller W, Kurth M, Lang A, Lees A, Lewitt P, et al. Levodopa in the treatment of Parkinson's disease: a consensus meeting. Movement Disorders : Official Journal of the Movement Disorder Society. 14: 911-3. PMID 10584663 DOI: 10.1002/1531-8257(199911)14:6<911::AID-MDS1001>3.0.CO;2-H  1
1999 Bennett MC, Bishop JF, Leng Y, Chock PB, Chase TN, Mouradian MM. Degradation of alpha-synuclein by proteasome. The Journal of Biological Chemistry. 274: 33855-8. PMID 10567343 DOI: 10.1074/jbc.274.48.33855  1
1999 Metman LV, Del Dotto P, LePoole K, Konitsiotis S, Fang J, Chase TN. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Archives of Neurology. 56: 1383-6. PMID 10555659 DOI: 10.1001/archneur.56.11.1383  1
1999 Blanchet PJ, Konitsiotis S, Whittemore ER, Zhou ZL, Woodward RM, Chase TN. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys. The Journal of Pharmacology and Experimental Therapeutics. 290: 1034-40. PMID 10454475  1
1999 Blanchet PJ, Fang J, Hyland K, Arnold LA, Mouradian MM, Chase TN. Short-term effects of high-dose 17beta-estradiol in postmenopausal PD patients: a crossover study. Neurology. 53: 91-5. PMID 10408542  1
1999 Fredriksson A, Palomo T, Chase T, Archer T. Tolerance to a suprathreshold dose of L-Dopa in MPTP mice: Effects of glutamate antagonists Journal of Neural Transmission. 106: 283-300. PMID 10392537 DOI: 10.1007/s007020050158  1
1999 Qin ZH, Chen RW, Wang Y, Nakai M, Chuang DM, Chase TN. Nuclear factor kappaB nuclear translocation upregulates c-Myc and p53 expression during NMDA receptor-mediated apoptosis in rat striatum. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 19: 4023-33. PMID 10234031  1
1999 Oh JD, Vaughan CL, Chase TN. Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits. Brain Research. 821: 433-42. PMID 10064831 DOI: 10.1016/S0006-8993(99)01121-X  1
1999 Oh JD, Russell DS, Vaughan CL, Chase TN. Corrigendum to: Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and L-DOPA administration Brain Research. 820: 117. PMID 10023039  1
1999 Nakai M, Qin ZH, Wang Y, Chase TN. Free radical scavenger OPC-14117 attenuates quinolinic acid-induced NF-kappaB activation and apoptosis in rat striatum. Brain Research. Molecular Brain Research. 64: 59-68. PMID 9889320 DOI: 10.1016/S0169-328X(98)00310-6  1
1998 Verhagen Metman L, Del Dotto P, Blanchet PJ, van den Munckhof P, Chase TN. Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Amino Acids. 14: 75-82. PMID 9871445 DOI: 10.1007/BF01345246  1
1998 Randolph C, Tierney MC, Mohr E, Chase TN. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. Journal of Clinical and Experimental Neuropsychology. 20: 310-9. PMID 9845158 DOI: 10.1076/jcen.20.3.310.823  1
1998 Blanchet PJ, Fang J, Gillespie M, Sabounjian L, Locke KW, Gammans R, Mouradian MM, Chase TN. Effects of the full dopamine D1 receptor agonist dihydrexidine in Parkinson's disease. Clinical Neuropharmacology. 21: 339-43. PMID 9844789  1
1998 Oh JD, Russell DS, Vaughan CL, Chase TN, Russell D. Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and L-DOPA administration. Brain Research. 813: 150-9. PMID 9824689 DOI: 10.1016/S0006-8993(98)01049-X  1
1998 Blanchet PJ, Konitsiotis S, Hyland K, Arnold LA, Pettigrew KD, Chase TN. Chronic exposure to MPTP as a primate model of progressive parkinsonism: a pilot study with a free radical scavenger. Experimental Neurology. 153: 214-22. PMID 9784281 DOI: 10.1006/exnr.1998.6906  1
1998 Blanchet PJ, Konitsiotis S, Chase TN. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Movement Disorders : Official Journal of the Movement Disorder Society. 13: 798-802. PMID 9756148 DOI: 10.1002/mds.870130507  1
1998 Fahn S, Clarence-Smith KE, Chase TN. Parkinson's disease: neurodegenerative mechanisms and neuroprotective interventions--report of a workshop. Movement Disorders : Official Journal of the Movement Disorder Society. 13: 759-67. PMID 9756143 DOI: 10.1002/mds.870130502  1
1998 Chase TN, Oh JD, Blanchet PJ. Neostriatal mechanisms in Parkinson's disease. Neurology. 51: S30-5. PMID 9711978  1
1998 Horstink MWIM, Praamstra P, Metman LV, Van den Munckhof P, Klaassen AAG, Blanchet P, Mouradian MM, Chase TN. Suprathreshold levodopa doses, dyskinesias, and disability in advanced Parkinson's disease [7] (multiple letters) Neurology. 51: 649-650. PMID 9710072  1
1998 Verhagen Metman L, Del Dotto P, Natté R, van den Munckhof P, Chase TN. Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease. Neurology. 51: 203-6. PMID 9674803  1
1998 Verhagen Metman L, Blanchet PJ, van den Munckhof P, Del Dotto P, Natté R, Chase TN. A trial of dextromethorphan in parkinsonian patients with motor response complications. Movement Disorders : Official Journal of the Movement Disorder Society. 13: 414-7. PMID 9613730 DOI: 10.1002/mds.870130307  1
1998 Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology. 50: 1323-6. PMID 9595981  1
1998 Chase TN. Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. Neurology. 50: S17-25. PMID 9591518  1
1998 Agid Y, Chase T, Marsden D. Adverse reactions to levodopa: drug toxicity or progression of disease? Lancet. 351: 851-2. PMID 9525359 DOI: 10.1016/S0140-6736(05)70285-3  1
1998 Colosimo C, Merello M, Hughes AJ, Sieradzan K, Lees AJ. Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications. Neurology. 50: 573-4. PMID 9484410  1
1998 Chase TN. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease. Drugs. 55: 1-9. PMID 9483164  1
1998 Qin ZH, Wang Y, Nakai M, Chase TN. Nuclear factor-kappa B contributes to excitotoxin-induced apoptosis in rat striatum. Molecular Pharmacology. 53: 33-42. PMID 9443930  1
1998 Verhagen Metman L, Del Dotto P, Van Den Munckhof P, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease | Amantadin zur behandlung von dyskinesien und motorischen fluktuationen beim morbus Parkinson Nervenheilkunde. 17: 480-484.  1
1997 Blesa R, Mohr E, Miletich RS, Randolph C, Hildebrand K, Sampson M, Chase TN. Changes in cerebral glucose metabolism with normal aging. European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. 4: 8-14. PMID 24283817 DOI: 10.1111/j.1468-1331.1997.tb00294.x  1
1997 Wang Y, Qin ZH, Nakai M, Chase TN. Glutamate metabotropic receptor agonist 1S,3R-ACPD induces internucleosomal DNA fragmentation and cell death in rat striatum. Brain Research. 772: 45-56. PMID 9406954 DOI: 10.1016/S0006-8993(97)00837-8  1
1997 Blanchet PJ, Konitsiotis S, Chase TN. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. The Journal of Pharmacology and Experimental Therapeutics. 283: 794-9. PMID 9353400  1
1997 Chase TN. A gene for Parkinson disease. Archives of Neurology. 54: 1156-7. PMID 9311360  1
1997 Metman LV, van den Munckhof P, Klaassen AA, Blanchet P, Mouradian MM, Chase TN. Effects of supra-threshold levodopa doses on dyskinesias in advanced Parkinson's disease. Neurology. 49: 711-3. PMID 9305328  1
1997 Mouradian MM, Chase TN. Gene therapy for Parkinson's disease: current knowledge and future perspective. Gene Therapy. 4: 504-6. PMID 9231065 DOI: 10.1038/sj.gt.3300449  1
1997 Oh JD, Del Dotto P, Chase TN. Protein kinase A inhibitor attenuates levodopa-induced motor response alterations in the hemi-parkinsonian rat. Neuroscience Letters. 228: 5-8. PMID 9197274 DOI: 10.1016/S0304-3940(97)00355-8  1
1997 Blanchet PJ, Papa SM, Metman LV, Mouradian MM, Chase TN. Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease. Neuroscience and Biobehavioral Reviews. 21: 447-53. PMID 9195602 DOI: 10.1016/S0149-7634(96)00038-3  1
1997 Mouradian MM, Chase TN. Gene therapy for Parkinson's disease: an approach to the prevention or palliation of levodopa-associated motor complications. Experimental Neurology. 144: 51-7. PMID 9126152 DOI: 10.1006/exnr.1996.6388  1
1997 Oyanagi K, Makifuchi T, Ohtoh T, Chen KM, Gajdusek DC, Chase TN. Distinct pathological features of the gallyas- and tau-positive glia in the Parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam. Journal of Neuropathology and Experimental Neurology. 56: 308-16. PMID 9056545  1
1997 Verhagen Metman L, Locatelli ER, Bravi D, Mouradian MM, Chase TN. Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications. Neurology. 48: 369-72. PMID 9040723  1
1996 Marin C, Papa S, Engber TM, Bonastre M, Tolosa E, Chase TN. MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats. Brain Research. 736: 202-5. PMID 8930325 DOI: 10.1016/0006-8993(96)00693-2  1
1996 Marin C, Engber TM, Bonastre M, Chase TN, Tolosa E. Effect of long-term haloperidol treatment on striatal neuropeptides: relation to stereotyped behavior. Brain Research. 731: 57-62. PMID 8883854 DOI: 10.1016/S0006-8993(96)00461-1  1
1996 Blesa R, Mohr E, Miletich RS, Hildebrand K, Sampson M, Chase TN. Cerebral metabolic changes in Alzheimer's disease: neurobehavioral patterns. Dementia (Basel, Switzerland). 7: 239-45. PMID 8872413  1
1996 Blanchet PJ, Metman LV, Mouradian MM, Chase TN. Acute pharmacologic blockade of dyskinesias in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 11: 580-1. PMID 8866502 DOI: 10.1002/mds.870110516  1
1996 Qin ZH, Wang Y, Chase TN. Stimulation of N-methyl-D-aspartate receptors induces apoptosis in rat brain. Brain Research. 725: 166-76. PMID 8836522 DOI: 10.1016/S0006-8993(96)00200-4  1
1996 Tedeschi G, Bertolino A, Lundbom N, Bonavita S, Patronas NJ, Duyn JH, Metman LV, Chase TN, Di Chiro G. Cortical and subcortical chemical pathology in Alzheimer's disease as assessed by multislice proton magnetic resonance spectroscopic imaging. Neurology. 47: 696-704. PMID 8797467  1
1996 Marin C, Engber TM, Chaudhuri P, Peppe A, Chase TN. Effects of kappa receptor agonists on D1 and D2 dopamine agonist and antagonist-induced behaviors. Psychopharmacology. 123: 215-21. PMID 8741947 DOI: 10.1007/BF02246181  1
1996 Metman LV, Blanchet PJ, de Jong D, Mouradian MM, Chase TN. Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 11: 257-60. PMID 8723141 DOI: 10.1002/mds.870110307  1
1996 Anderson JJ, Kask AM, Chase TN. Effects of cannabinoid receptor stimulation and blockade on catalepsy produced by dopamine receptor antagonists. European Journal of Pharmacology. 295: 163-8. PMID 8720580 DOI: 10.1016/0014-2999(95)00661-3  1
1996 Papa SM, Chase TN. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Annals of Neurology. 39: 574-8. PMID 8619541 DOI: 10.1002/ana.410390505  1
1996 Chase TN, Engber TM, Mouradian MM. Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease. Advances in Neurology. 69: 497-501. PMID 8615171  1
1995 Mohr E, Brouwers P, Claus JJ, Purdon SE, Gagnon M, Chase TN. Differential classification of dementia. Behavioural Neurology. 8: 23-30. PMID 24487399 DOI: 10.3233/BEN-1995-8103  1
1995 Papa SM, Boldry RC, Engber TM, Kask AM, Chase TN. Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade. Brain Research. 701: 13-8. PMID 8925275 DOI: 10.1016/0006-8993(95)00924-3  1
1995 Braun AR, Randolph C, Stoetter B, Mohr E, Cox C, Vladar K, Sexton R, Carson RE, Herscovitch P, Chase TN. The functional neuroanatomy of Tourette's syndrome: an FDG-PET Study. II: Relationships between regional cerebral metabolism and associated behavioral and cognitive features of the illness. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 13: 151-68. PMID 8597526 DOI: 10.1016/0893-133X(95)00052-F  1
1995 Anderson LA, Anderson JJ, Chase TN, Walters JR. The cannabinoid agonists WIN 55,212-2 and CP 55,940 attenuate rotational behavior induced by a dopamine D1 but not a D2 agonist in rats with unilateral lesions of the nigrostriatal pathway. Brain Research. 691: 106-14. PMID 8590042 DOI: 10.1016/0006-8993(95)00645-7  1
1995 Boldry RC, Papa SM, Kask AM, Chase TN. MK-801 reverses effects of chronic levodopa on D1 and D2 dopamine agonist-induced rotational behavior. Brain Research. 692: 259-64. PMID 8548312 DOI: 10.1016/0006-8993(95)00690-R  1
1995 Randolph C, Tierney MC, Chase TN. Implicit memory in Alzheimer's disease. Journal of Clinical and Experimental Neuropsychology. 17: 343-51. PMID 7650098 DOI: 10.1080/01688639508405128  1
1995 Anderson JJ, Randall S, Chase TN. The neurokinin1 receptor antagonist CP-99,994 reduces catalepsy produced by the dopamine D2 receptor antagonist raclopride: correlation with extracellular acetylcholine levels in striatum. The Journal of Pharmacology and Experimental Therapeutics. 274: 928-36. PMID 7636756  1
1995 Chase TN, Tamminga CA. Alzheimer's dementia. The American Journal of Psychiatry. 152: 1110. PMID 7625456  1
1995 Marin C, Chase TN. Effects of SCH 32615, an enkephalinase inhibitor, on D-1 and D-2 dopamine receptor-mediated behaviors. Neuropharmacology. 34: 677-82. PMID 7566505 DOI: 10.1016/0028-3908(95)00026-3  1
1995 Blesa R, Mohr E, Miletich RS, Chase TN. Limbic system dysfunction in Alzheimer's disease. Journal of Neurology, Neurosurgery, and Psychiatry. 59: 450-1. PMID 7561934 DOI: 10.1136/jnnp.59.4.450-a  1
1995 Chase TN, Metman LV, Bravi D, Roberts JW, Sibley DR, Mouradian MM. Dopamine-receptor subtype-selective agonists in the treatment of Parkinson's disease Clinical Neuropharmacology. 18: S207-S215.  1
1995 Carlsson A, Chase TN, Willner P, Schwartz JC. Towards a new understanding of dopamine receptors Clinical Neuropharmacology. 18: S6-S13.  1
1995 Bedard PJ, Gomez-Mancilla B, Blanchet P, Grondin R, DiPaolo T, Sethy, Piercey MF, Chase TN, Wise RA, Perlmutter JS, Ranhoksy. Dopamine-receptor families and the treatment of Parkinson's disease Clinical Neuropharmacology. 18: S178-S187.  1
1995 Mierau J, Bedard PJ, Van Tol, Willner P, Schatzberg, Piercey MF, Chase TN, Sethy, Ranhosky. Pramipexole: A dopamine-receptor agonist for treatment of Parkinson's disease Clinical Neuropharmacology. 18: S195-S206.  1
1995 Gerfen CR, Piercey MF, Wise RA, Carlsson A, Chase TN, Farde L, Willner P. Dopamine receptor function in the basal ganglia Clinical Neuropharmacology. 18: S162-S177.  1
1995 Schatzberg AF, Posener JA, Rothschild AJ, Piercey MF, Willner P, Chase TN. The role of dopamine in psychotic depression Clinical Neuropharmacology. 18: S66-S73.  1
1994 Blin J, Ray CA, Piercey MF, Bartko JJ, Mouradian MM, Chase TN. Comparison of cholinergic drug effects on regional brain glucose consumption in rats and humans by means of autoradiography and position emission tomography. Brain Research. 635: 196-202. PMID 8173955 DOI: 10.1016/0006-8993(94)91439-7  1
1994 Sohn YH, Metman LV, Bravi D, Linfante I, Aotsuka A, Mouradian MM, Chase TN. Levodopa peak response time reflects severity of dopamine neuron loss in Parkinson's disease. Neurology. 44: 755-7. PMID 8164839  1
1994 Blin J, Piercey MF, Giuffra ME, Mouradian MM, Chase TN. Metabolic effects of scopolamine and physostigmine in human brain measured by positron emission tomography. Journal of the Neurological Sciences. 123: 44-51. PMID 8064320 DOI: 10.1016/0022-510X(94)90202-X  1
1994 Litvan I, Blesa R, Clark K, Nichelli P, Atack JR, Mouradian MM, Grafman J, Chase TN. Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy. Annals of Neurology. 36: 55-61. PMID 8024262 DOI: 10.1002/ana.410360112  1
1994 Bravi D, Mouradian MM, Roberts JW, Davis TL, Sohn YH, Chase TN. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms. Annals of Neurology. 36: 27-31. PMID 8024257 DOI: 10.1002/ana.410360108  1
1994 Engber TM, Anderson JJ, Boldry RC, Papa SM, Kuo S, Chase TN. Excitatory amino acid receptor antagonists modify regional cerebral metabolic responses to levodopa in 6-hydroxydopamine-lesioned rats. Neuroscience. 59: 389-99. PMID 8008198 DOI: 10.1016/0306-4522(94)90604-1  1
1994 Metman LV, Sethy VH, Roberts JR, Bravi D, Hoff JI, Mouradian MM, Chase TN. Motor effects of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 9: 577-81. PMID 7990854 DOI: 10.1002/mds.870090512  1
1994 Randolph C, Roberts JW, Tierney MC, Bravi D, Mouradian MM, Chase TN. D-cycloserine treatment of Alzheimer disease. Alzheimer Disease and Associated Disorders. 8: 198-205. PMID 7986489  1
1994 Oyanagi K, Makifuchi T, Ohtoh T, Chen KM, Gajdusek DC, Chase TN, Ikuta F. The neostriatum and nucleus accumbens in parkinsonism-dementia complex of Guam: a pathological comparison with Alzheimer's disease and progressive supranuclear palsy. Acta Neuropathologica. 88: 122-8. PMID 7985492 DOI: 10.1007/BF00294504  1
1994 Metman LV, Hoff J, Mouradian MM, Chase TN. Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa. Movement Disorders : Official Journal of the Movement Disorder Society. 9: 463-5. PMID 7969216 DOI: 10.1002/mds.870090416  1
1994 Anderson JJ, Kuo S, Chase TN, Engber TM. Dopamine D1 receptor-stimulated release of acetylcholine in rat striatum is mediated indirectly by activation of striatal neurokinin1 receptors. The Journal of Pharmacology and Experimental Therapeutics. 269: 1144-51. PMID 7912277  1
1994 Papa SM, Engber TM, Kask AM, Chase TN. Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Research. 662: 69-74. PMID 7859092 DOI: 10.1016/0006-8993(94)90796-X  1
1994 Oyanagi K, Makifuchi T, Ohtoh T, Chen KM, van der Schaaf T, Gajdusek DC, Chase TN, Ikuta F. Amyotrophic lateral sclerosis of Guam: the nature of the neuropathological findings. Acta Neuropathologica. 88: 405-12. PMID 7847068 DOI: 10.1007/BF00389491  1
1994 Oyanagi K, Makifuchi T, Ohtoh T, Ikuta F, Chen KM, Chase TN, Gajdusek DC. Topographic investigation of brain atrophy in parkinsonism-dementia complex of Guam: a comparison with Alzheimer's disease and progressive supranuclear palsy. Neurodegeneration : a Journal For Neurodegenerative Disorders, Neuroprotection, and Neuroregeneration. 3: 301-4. PMID 7842300  1
1994 Anderson JJ, Kuo S, Chase TN. Endogenous excitatory amino acids tonically stimulate striatal acetylcholine release through NMDA but not AMPA receptors. Neuroscience Letters. 176: 264-8. PMID 7830961 DOI: 10.1016/0304-3940(94)90097-3  1
1994 Engber TM, Papa SM, Boldry RC, Chase TN. NMDA receptor blockade reverses motor response alterations induced by levodopa. Neuroreport. 5: 2586-8. PMID 7696610  1
1994 Chase TN, Engber TM, Mouradian MM. Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease. Neurology. 44: S15-8. PMID 7519334  1
1993 Marin C, Parashos SA, Kapitzoglou-Logothetis V, Peppe A, Chase TN. D1 and D2 dopamine receptor-mediated mechanisms and behavioral supersensitivity. Pharmacology, Biochemistry, and Behavior. 45: 195-200. PMID 8516358 DOI: 10.1016/0091-3057(93)90104-2  1
1993 Anderson JJ, Bravi D, Ferrari R, Davis TL, Baronti F, Chase TN, Dagani F. No evidence for altered muscle mitochondrial function in Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry. 56: 477-80. PMID 8505638 DOI: 10.1136/jnnp.56.5.477  1
1993 Peppe A, Dambrosia JM, Chase TN. Risk factors for motor response complications in L-dopa-treated parkinsonian patients. Advances in Neurology. 60: 698-702. PMID 8420213  1
1993 Chase TN, Engber TM, Mouradian MM. Striatal dopaminoceptive system changes and motor response complications in L-dopa-treated patients with advanced Parkinson's disease. Advances in Neurology. 60: 181-5. PMID 8420133  1
1993 Bravi D, Mouradian MM, Roberts JW, Davis TL, Chase TN. End-of-dose dystonia in Parkinson's disease. Neurology. 43: 2130-1. PMID 8413978  1
1993 Papa SM, Engber TM, Boldry RC, Chase TN. Opposite effects of NMDA and AMPA receptor blockade on catalepsy induced by dopamine receptor antagonists. European Journal of Pharmacology. 232: 247-53. PMID 8385618 DOI: 10.1016/0014-2999(93)90781-C  1
1993 Giuffra ME, Sethy VH, Davis TL, Mouradian MM, Chase TN. Milacemide therapy for Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 8: 47-50. PMID 8380487 DOI: 10.1002/mds.870080109  1
1993 Jauch DA, Sethy VH, Weick BG, Chase TN, Schwarcz R. Intravenous administration of L-kynurenine to rhesus monkeys: effect on quinolinate and kynurenate levels in serum and cerebrospinal fluid. Neuropharmacology. 32: 467-72. PMID 8321427 DOI: 10.1016/0028-3908(93)90171-X  1
1993 Braun AR, Stoetter B, Randolph C, Hsiao JK, Vladar K, Gernert J, Carson RE, Herscovitch P, Chase TN. The functional neuroanatomy of Tourette's syndrome: an FDG-PET study. I. Regional changes in cerebral glucose metabolism differentiating patients and controls. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 9: 277-91. PMID 8305128 DOI: 10.1038/npp.1993.64  1
1993 Randolph C, Mohr E, Chase TN. Assessment of intellectual function in dementing disorders: validity of WAIS-R short forms for patients with Alzheimer's, Huntington's, and Parkinson's disease. Journal of Clinical and Experimental Neuropsychology. 15: 743-53. PMID 8276933 DOI: 10.1080/01688639308402593  1
1993 Chase TN, Mouradian MM, Engber TM. Motor response complications and the function of striatal efferent systems. Neurology. 43: S23-7. PMID 8264907  1
1993 Roberts JW, Cora-Locatelli G, Bravi D, Amantea MA, Mouradian MM, Chase TN. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology. 43: 2685-8. PMID 8255478  1
1993 Anderson JJ, Kuo S, Chase TN, Engber TM. GABAA and GABAB receptors differentially regulate striatal acetylcholine release in vivo. Neuroscience Letters. 160: 126-30. PMID 8247341 DOI: 10.1016/0304-3940(93)90395-2  1
1993 Giuffra M, Mouradian MM, Davis TL, Ownby J, Chase TN. Dynorphin agonist therapy of Parkinson's disease. Clinical Neuropharmacology. 16: 444-7. PMID 8106151  1
1993 Engber TM, Marin C, Susel Z, Chase TN. Differential effects of chronic dopamine D1 and D2 receptor agonists on rotational behavior and dopamine receptor binding. European Journal of Pharmacology. 236: 385-93. PMID 8102970 DOI: 10.1016/0014-2999(93)90476-X  1
1993 Engber TM, Anderson JJ, Boldry RC, Kuo S, Chase TN. N-methyl-D-aspartate receptor blockade differentially modifies regional cerebral metabolic responses to D1 and D2 dopamine agonists in rats with a unilateral 6-hydroxydopamine lesion. Neuroscience. 54: 1051-61. PMID 8101981 DOI: 10.1016/0306-4522(93)90595-7  1
1993 Bravi D, Davis TL, Mouradian MM, Chase TN. Treatment of Parkinson's disease with the partial dopamine agonist EMD 49980. Movement Disorders : Official Journal of the Movement Disorder Society. 8: 195-7. PMID 8097280 DOI: 10.1002/mds.870080214  1
1993 Marin C, Chase TN. Dopamine D1 receptor stimulation but not dopamine D2 receptor stimulation attenuates haloperidol-induced behavioral supersensitivity and receptor up-regulation. European Journal of Pharmacology. 231: 191-6. PMID 8095897 DOI: 10.1016/0014-2999(93)90448-Q  1
1993 Boldry RC, Chase TN, Engber TM. Influence of previous exposure to levodopa on the interaction between dizocilpine and dopamine D1 and D2 agonists in rats with 6-hydroxydopamine-induced lesions. The Journal of Pharmacology and Experimental Therapeutics. 267: 1454-9. PMID 7903390  1
1993 Anderson JJ, Chase TN, Engber TM. Substance P increases release of acetylcholine in the dorsal striatum of freely moving rats. Brain Research. 623: 189-94. PMID 7693302 DOI: 10.1016/0006-8993(93)91426-S  1
1993 Boldry RC, Kelland MD, Engber TM, Chase TN. NBQX inhibits AMPA-induced locomotion after injection into the nucleus accumbens. Brain Research. 600: 331-4. PMID 7679606 DOI: 10.1016/0006-8993(93)91392-6  1
1993 Randolph C, Braun AR, Goldberg TE, Chase TN. Semantic Fluency in Alzheimer's, Parkinson's, and Huntington's Disease: Dissociation of Storage and Retrieval Failures Neuropsychology. 7: 82-88.  1
1992 Mohr E, Mann UM, Miletich RS, Sampson M, Goldberg TE, Grimes JD, Chase TN. Neuropsychological and glucose metabolic profiles in asymmetric Parkinson's disease. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques. 19: 163-9. PMID 1623440 DOI: 10.1017/S0317167100042207  1
1992 Bravi D, Anderson JJ, Dagani F, Davis TL, Ferrari R, Gillespie M, Chase TN. Effect of aging and dopaminomimetic therapy on mitochondrial respiratory function in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 7: 228-31. PMID 1620140 DOI: 10.1002/mds.870070307  1
1992 Baronti F, Davis TL, Boldry RC, Mouradian MM, Chase TN. Deprenyl effects on levodopa pharmacodynamics, mood, and free radical scavenging. Neurology. 42: 541-4. PMID 1549214  1
1992 Heuser IJ, Baronti F, Marin CA, Ma N, Merriam GR, Chase TN, Mouradian MM. Growth hormone secretion in Alzheimer's disease: 24-hour profile of basal levels and response to stimulation and suppression studies. Neurobiology of Aging. 13: 255-60. PMID 1522942 DOI: 10.1016/0197-4580(92)90037-X  1
1992 Weinberger DR, Jones D, Reba RC, Mann U, Coppola R, Gibson R, Gorey J, Braun A, Chase TN. A comparison of FDG PET and IQNB SPECT in normal subjects and in patients with dementia. The Journal of Neuropsychiatry and Clinical Neurosciences. 4: 239-48. PMID 1498576  1
1992 Dagani F, Anderson JJ, Chase TN. Mitochondrial function in Parkinson's disease. Annals of Neurology. 32: 226-7. PMID 1472244 DOI: 10.1002/ana.410320219  1
1992 Baronti F, Mouradian MM, Davis TL, Giuffra M, Brughitta G, Conant KE, Chase TN. Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease. Annals of Neurology. 32: 776-81. PMID 1471868 DOI: 10.1002/ana.410320611  1
1992 Mann UM, Mohr E, Gearing M, Chase TN. Heterogeneity in Alzheimer's disease: progression rate segregated by distinct neuropsychological and cerebral metabolic profiles. Journal of Neurology, Neurosurgery, and Psychiatry. 55: 956-9. PMID 1431960 DOI: 10.1136/jnnp.55.10.956  1
1992 Stoetter B, Braun AR, Randolph C, Gernert J, Carson RE, Herscovitch P, Chase TN. Functional neuroanatomy of Tourette syndrome. Limbic-motor interactions studied with FDG PET. Advances in Neurology. 58: 213-26. PMID 1414626  1
1992 Litvan I, Berrettini WH, Atack JR, Chase TN. CSF galanin and neuropeptide Y immunoreactivity in progressive supranuclear palsy. Acta Neurologica Scandinavica. 86: 204-6. PMID 1384261  1
1992 Engber TM, Susel Z, Weick BG, Walters JR, Chase TN. Effects of chronic levodopa on D1 and D2 receptor-mediated striatal output. Neurochemistry International. 20: 255S-260S. PMID 1365437 DOI: 10.1016/0197-0186(92)90248-P  1
1992 Anderson JJ, Chase TN, Engber TM. Differential effect of subthalamic nucleus ablation on dopamine D1 and D2 agonist-induced rotation in 6-hydroxydopamine-lesioned rats. Brain Research. 588: 307-10. PMID 1356592 DOI: 10.1016/0006-8993(92)91591-2  1
1992 Engber TM, Boldry RC, Kuo S, Chase TN. Dopaminergic modulation of striatal neuropeptides: differential effects of D1 and D2 receptor stimulation on somatostatin, neuropeptide Y, neurotensin, dynorphin and enkephalin. Brain Research. 581: 261-8. PMID 1356580 DOI: 10.1016/0006-8993(92)90716-M  1
1992 Baronti F, Mouradian MM, Conant KE, Giuffra M, Brughitta G, Chase TN. Partial dopamine agonist therapy of levodopa-induced dyskinesias. Neurology. 42: 1241-3. PMID 1351273  1
1992 Giuffra ME, Mouradian MM, Chase TN. Glutamatergic therapy of Huntington's chorea. Clinical Neuropharmacology. 15: 148-51. PMID 1350513  1
1991 Claus JJ, Mohr E, Chase TN. Clinical trials in dementia: learning effects with repeated testing. Journal of Psychiatry & Neuroscience : Jpn. 16: 1-4. PMID 2049365  1
1991 Claus JJ, Ludwig C, Mohr E, Giuffra M, Blin J, Chase TN. Nootropic drugs in Alzheimer's disease: symptomatic treatment with pramiracetam. Neurology. 41: 570-4. PMID 2011259  1
1991 Litvan I, Mohr E, Williams J, Gomez C, Chase TN. Differential memory and executive functions in demented patients with Parkinson's and Alzheimer's disease. Journal of Neurology, Neurosurgery, and Psychiatry. 54: 25-9. PMID 2010755  1
1991 Atack JR, Litvan I, Thal LJ, May C, Rapoport SI, Chase TN. Cerebrospinal fluid acetylcholinesterase in progressive supranuclear palsy: reduced activity relative to normal subjects and lack of inhibition by oral physostigmine. Journal of Neurology, Neurosurgery, and Psychiatry. 54: 832-5. PMID 1955905 DOI: 10.1136/jnnp.54.9.832  1
1991 Mouradian MM, Heuser IJ, Baronti F, Giuffra M, Conant K, Davis TL, Chase TN. Comparison of the clinical pharmacology of (-)NPA and levodopa in Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry. 54: 401-5. PMID 1865201  1
1991 Mohr E, Brouwers P, Claus JJ, Mann UM, Fedio P, Chase TN. Visuospatial cognition in Huntington's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 6: 127-32. PMID 1829137 DOI: 10.1002/mds.870060207  1
1991 Ariano MA, Engber TM, Susel Z, Chase TN. Striatal D1 dopamine receptor morphochemistry following continuous or intermittent L-dopa replacement therapy. Experimental Neurology. 112: 112-8. PMID 1826481 DOI: 10.1016/0014-4886(91)90120-2  1
1991 Baronti F, Ruggieri S, Mouradian MM, Bonamartini A, Bocciarelli P, De Pandis MF, Chase TN, Agnoli A. [Changes in the nigrostriatal dopamine receptor compartment after continuous dopaminergic infusions in Parkinson disease]. Rivista Di Neurologia. 61: 210-4. PMID 1813972  1
1991 Mouradian MM, Blin J, Giuffra M, Heuser IJ, Baronti F, Ownby J, Chase TN. Somatostatin replacement therapy for Alzheimer dementia. Annals of Neurology. 30: 610-3. PMID 1789687 DOI: 10.1002/ana.410300415  1
1991 Engber TM, Susel Z, Kuo S, Gerfen CR, Chase TN. Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats. Brain Research. 552: 113-8. PMID 1717109 DOI: 10.1016/0006-8993(91)90667-K  1
1991 Baronti F, Conant KE, Giuffra M, Davis TL, Brughitta G, Iadarola MJ, Berrettini WH, Chase TN, Mouradian MM. Opioid peptides in Parkinson's disease: effects of dopamine repletion. Brain Research. 560: 92-6. PMID 1684735 DOI: 10.1016/0006-8993(91)91219-Q  1
1991 Dagani F, Ferrari R, Anderson JJ, Chase TN. L-dopa does not affect electron transfer chain enzymes and respiration of rat muscle mitochondria. Movement Disorders : Official Journal of the Movement Disorder Society. 6: 315-9. PMID 1661844 DOI: 10.1002/mds.870060408  1
1990 Mohr E, Juncos J, Cox C, Litvan I, Fedio P, Chase TN. Selective deficits in cognition and memory in high-functioning parkinsonian patients. Journal of Neurology, Neurosurgery, and Psychiatry. 53: 603-6. PMID 2391526  1
1990 Mohr E, Cox C, Williams J, Chase TN, Fedio P. Impairment of central auditory function in Alzheimer's disease. Journal of Clinical and Experimental Neuropsychology. 12: 235-46. PMID 2341553 DOI: 10.1080/01688639008400970  1
1990 Mouradian MM, Heuser IJ, Baronti F, Chase TN. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Annals of Neurology. 27: 18-23. PMID 2301923 DOI: 10.1002/ana.410270105  1
1990 Pan HS, Engber TM, Chase TN, Walters JR. The effects of striatal lesion on turning behavior and globus pallidus single unit response to dopamine agonist administration. Life Sciences. 46: 73-80. PMID 2299971 DOI: 10.1016/0024-3205(90)90060-5  1
1990 Weinberger DR, Mann U, Gibson RE, Coppola R, Jones DW, Braun AR, Berman KF, Sunderland T, Reba RC, Chase TN. Cerebral muscarinic receptors in primary degenerative dementia as evaluated by SPECT with iodine-123-labeled QNB. Advances in Neurology. 51: 147-50. PMID 2294653  1
1990 Chase TN, Fabbrini G, Juncos JL, Mouradian MM. Motor response complications with chronic levodopa therapy. Advances in Neurology. 53: 377-81. PMID 2239478  1
1990 Mohr E, Litvan I, Williams J, Fedio P, Chase TN. Selective deficits in Alzheimer and parkinsonian dementia: visuospatial function. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques. 17: 292-7. PMID 2207883  1
1990 Gerfen CR, Engber TM, Mahan LC, Susel Z, Chase TN, Monsma FJ, Sibley DR. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science (New York, N.Y.). 250: 1429-32. PMID 2147780  1
1990 Weick BG, Engber TM, Susel Z, Chase TN, Walters JR. Responses of substantia nigra pars reticulata neurons to GABA and SKF 38393 in 6-hydroxydopamine-lesioned rats are differentially affected by continuous and intermittent levodopa administration. Brain Research. 523: 16-22. PMID 2119854 DOI: 10.1016/0006-8993(90)91631-P  1
1990 Mohr E, Mann UM, Chase TN. Subgroups in Alzheimer's disease: fact or fiction? Psychiatric Journal of the University of Ottawa : Revue De Psychiatrie De L'Université D'Ottawa. 15: 203-6. PMID 1980952  1
1989 Litvan I, Gomez C, Atack JR, Gillespie M, Kask AM, Mouradian MM, Chase TN. Physostigmine treatment of progressive supranuclear palsy. Annals of Neurology. 26: 404-7. PMID 2802540 DOI: 10.1002/ana.410260318  1
1989 Mouradian MM, Heuser IJ, Baronti F, Fabbrini G, Juncos JL, Chase TN. Pathogenesis of dyskinesias in Parkinson's disease. Annals of Neurology. 25: 523-6. PMID 2774496 DOI: 10.1002/ana.410250521  1
1989 Chase TN, Baronti F, Fabbrini G, Heuser IJ, Juncos JL, Mouradian MM. Rationale for continuous dopaminomimetic therapy of Parkinson's disease. Neurology. 39: 7-10; discussion 19. PMID 2685653  1
1989 Mohr E, Schlegel J, Fabbrini G, Williams J, Mouradian MM, Mann UM, Claus JJ, Fedio P, Chase TN. Clonidine treatment of Alzheimer's disease. Archives of Neurology. 46: 376-8. PMID 2650662 DOI: 10.1001/archneur.1989.00520400030015  1
1989 Mann UM, Mohr E, Chase TN. Rapidly progressive Alzheimer's disease. Lancet. 2: 799. PMID 2571032 DOI: 10.1016/S0140-6736(89)90857-X  1
1989 Braun A, Mouradian MM, Mohr E, Fabbrini G, Chase TN. Selective D-1 dopamine receptor agonist effects in hyperkinetic extrapyramidal disorders. Journal of Neurology, Neurosurgery, and Psychiatry. 52: 631-5. PMID 2567345  1
1989 Schlegel J, Mohr E, Williams J, Mann U, Gearing M, Chase TN. Guanfacine treatment of Alzheimer's disease. Clinical Neuropharmacology. 12: 124-8. PMID 2566381  1
1989 Mohr E, Fabbrini G, Williams J, Schlegel J, Cox C, Fedio P, Chase TN. Dopamine and memory function in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 4: 113-20. PMID 2543918 DOI: 10.1002/mds.870040202  1
1989 Mourdian MM, Heyes MP, Pan JB, Heuser IJ, Markey SP, Chase TN, Mouradian MM. No changes in central quinolinic acid levels in Alzheimer's disease. Neuroscience Letters. 105: 233-8. PMID 2535006 DOI: 10.1016/0304-3940(89)90043-8  1
1988 Pullman SL, Watts RL, Juncos JL, Chase TN, Sanes JN. Dopaminergic effects on simple and choice reaction time performance in Parkinson's disease. Neurology. 38: 249-54. PMID 3340288  1
1988 Mouradian MM, Mohr E, Williams JA, Chase TN. No response to high-dose muscarinic agonist therapy in Alzheimer's disease. Neurology. 38: 606-8. PMID 3281057  1
1988 Braun AR, Chase TN. Behavioral effects of chronic exposure to selective D-1 and D-2 dopamine receptor agonists. European Journal of Pharmacology. 147: 441-51. PMID 3259931 DOI: 10.1016/0014-2999(88)90179-3  1
1988 Fabbrini G, Mouradian MM, Juncos JL, Schlegel J, Mohr E, Chase TN. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I. Annals of Neurology. 24: 366-71. PMID 3228270 DOI: 10.1002/ana.410240303  1
1988 Chase TN, Juncos JL, Fabbrini G, Mouradian MM. Motor response complications in advanced Parkinson's disease. Functional Neurology. 3: 429-36. PMID 3072278  1
1988 Mouradian MM, Chase TN. Central mechanisms and levodopa response fluctuations in Parkinson's disease. Clinical Neuropharmacology. 11: 378-85. PMID 3061637  1
1988 Weinberger DR, Berman KF, Chase TN. Mesocortical dopaminergic function and human cognition. Annals of the New York Academy of Sciences. 537: 330-8. PMID 2974264  1
1988 Fabbrini G, Braun A, Mouradian MM, Tamminga CA, Chase TN. Dopamine D-1 receptor agonist stimulation of prolactin secretion in man. Journal of Neural Transmission. 71: 159-63. PMID 2965754 DOI: 10.1007/BF01245709  1
1988 Mouradian MM, Contreras PC, Monahan JB, Chase TN. [3H]MK-801 binding in Alzheimer's disease. Neuroscience Letters. 93: 225-30. PMID 2853845 DOI: 10.1016/0304-3940(88)90086-9  1
1987 Mohr E, Fabbrini G, Ruggieri S, Fedio P, Chase TN. Cognitive concomitants of dopamine system stimulation in parkinsonian patients. Journal of Neurology, Neurosurgery, and Psychiatry. 50: 1192-6. PMID 3668568 DOI: 10.1136/jnnp.50.9.1192  1
1987 Mouradian MM, Juncos JL, Serrati C, Fabbrini G, Palmeri S, Chase TN. Exercise and the antiparkinsonian response to levodopa. Clinical Neuropharmacology. 10: 351-5. PMID 3503678  1
1987 Tamminga CA, Foster NL, Fedio P, Bird ED, Chase TN. Alzheimer's disease: low cerebral somatostatin levels correlate with impaired cognitive function and cortical metabolism. Neurology. 37: 161-5. PMID 2879258  1
1987 Chase TN, Burrows GH, Mohr E. Cortical glucose utilization patterns in primary degenerative dementias of the anterior and posterior type. Archives of Gerontology and Geriatrics. 6: 289-97. PMID 2446576 DOI: 10.1016/0167-4943(87)90028-8  1
1986 Foster NL, Tamminga CA, O'Donohue TL, Tanimoto K, Bird ED, Chase TN. Brain choline acetyltransferase activity and neuropeptide Y concentrations in Alzheimer's disease. Neuroscience Letters. 63: 71-5. PMID 3754039 DOI: 10.1016/0304-3940(86)90015-7  1
1986 Bruno G, Mohr E, Gillespie M, Fedio P, Chase TN. Muscarinic agonist therapy of Alzheimer's disease. A clinical trial of RS-86. Archives of Neurology. 43: 659-61. PMID 3524514 DOI: 10.1001/archneur.1986.00520070017009  1
1986 Mouradian MM, Farah JM, Mohr E, Fabbrini G, O'Donohue TL, Chase TN. Spinal fluid CRF reduction in Alzheimer's disease. Neuropeptides. 8: 393-400. PMID 3493444 DOI: 10.1016/0143-4179(86)90010-7  1
1986 Braun AR, Chase TN. Obligatory D-1/D-2 receptor interaction in the generation of dopamine agonist related behaviors. European Journal of Pharmacology. 131: 301-6. PMID 3493161 DOI: 10.1016/0014-2999(86)90588-1  1
1986 Martin A, Brouwers P, Lalonde F, Cox C, Teleska P, Fedio P, Foster NL, Chase TN. Towards a behavioral typology of Alzheimer's patients. Journal of Clinical and Experimental Neuropsychology. 8: 594-610. PMID 3492510  1
1986 Foster NL, Chase TN, Patronas NJ, Gillespie MM, Fedio P. Cerebral mapping of apraxia in Alzheimer's disease by positron emission tomography. Annals of Neurology. 19: 139-43. PMID 3485952 DOI: 10.1002/ana.410190205  1
1986 Barone P, Braun AR, Chase TN. D-1/D-2 dopamine receptor interactions in the regulation of extrapyramidal motor function: studies in animal models and parkinsonian patients. Clinical Neuropharmacology. 9: 128-30. PMID 2952266  1
1986 Braun AR, Barone P, Chase TN. Interaction of D1 and D2 dopamine receptors in the expression of dopamine agonist induced behaviors. Advances in Experimental Medicine and Biology. 204: 151-66. PMID 2947426  1
1986 Simmons JT, Pastakia B, Chase TN, Shults CW. Magnetic resonance imaging in Huntington disease. Ajnr. American Journal of Neuroradiology. 7: 25-8. PMID 2937278  1
1986 Shults C, Steardo L, Barone P, Mohr E, Juncos J, Serrati C, Fedio P, Tamminga CA, Chase TN. Huntington's disease: effect of cysteamine, a somatostatin-depleting agent. Neurology. 36: 1099-102. PMID 2874527  1
1986 Mohr E, Bruno G, Foster N, Gillespie M, Cox C, Hare TA, Tamminga C, Fedio P, Chase TN. GABA-agonist therapy for Alzheimer's disease. Clinical Neuropharmacology. 9: 257-63. PMID 2872956  1
1986 Barone P, Davis TA, Braun AR, Chase TN. Dopaminergic mechanisms and motor function: characterization of D-1 and D-2 dopamine receptor interactions. European Journal of Pharmacology. 123: 109-14. PMID 2872071 DOI: 10.1016/0014-2999(86)90694-1  1
1986 Schlesinger K, Pelleymounter MA, van de Kamp J, Bader DL, Stewart JM, Chase TN. Substance P facilitation of memory: effects in an appetitively motivated learning task. Behavioral and Neural Biology. 45: 230-9. PMID 2421708 DOI: 10.1016/S0163-1047(86)90805-8  1
1985 Steardo L, Monteleone P, Tamminga CA, Canonico PL, Denman D, Scapagnini U, Chase TN. Differential responses in prolactin levels induced by naloxone in humans. Psychoneuroendocrinology. 10: 203-9. PMID 4034850 DOI: 10.1016/0306-4530(85)90058-7  1
1985 Newman RP, LeWitt PA, Shults C, Bruno G, Foster NL, Chase TN, Calne DB. Dystonia: treatment with bromocriptine. Clinical Neuropharmacology. 8: 328-33. PMID 3907823  1
1985 Knight M, Barone P, Tamminga CA, Steardo L, Chase TN. Cholecystokinin octapeptide analogues stable to brain proteolysis. Peptides. 6: 631-4. PMID 2999729 DOI: 10.1016/0196-9781(85)90165-2  1
1985 Shults CW, Buck SH, Burcher E, Chase TN, O'Donohue TL. Distinct binding sites for substance P and neurokinin A (substance K): co-transmitters in rat brain. Peptides. 6: 343-5. PMID 2994025 DOI: 10.1016/0196-9781(85)90060-9  1
1985 Steardo L, Knight M, Tamminga CA, Chase TN. Products of cholecystokinin (CCK)-octapeptide proteolysis interact with central CCK receptors. Neuroscience Letters. 54: 319-25. PMID 2986058  1
1985 Tamminga CA, Foster NL, Chase TN. Reduced brain somatostatin levels in Alzheimer's disease. The New England Journal of Medicine. 313: 1294-5. PMID 2865676 DOI: 10.1056/NEJM198511143132017  1
1985 Massari VJ, Shults CW, Park CH, Tizabi Y, Moody TW, Chronwall BM, Culver M, Chase TN. Deafferentation causes a loss of presynaptic bombesin receptors and supersensitivity of substance P receptors in the dorsal horn of the cat spinal cord. Brain Research. 343: 268-74. PMID 2413960 DOI: 10.1016/0006-8993(85)90744-9  1
1985 Shults CW, Yajima H, Gullner HG, Chase TN, O'Donohue TL. Demonstration and distribution of kassinin-like material (substance K) in the rat central nervous system. Journal of Neurochemistry. 45: 552-8. PMID 2409232 DOI: 10.1111/j.1471-4159.1985.tb04023.x  1
1984 Foster NL, Chase TN, Mansi L, Brooks R, Fedio P, Patronas NJ, Di Chiro G. Cortical abnormalities in Alzheimer's disease. Annals of Neurology. 16: 649-54. PMID 6335378 DOI: 10.1002/ana.410160605  1
1984 Chase TN, Fedio P, Foster NL, Brooks R, Di Chiro G, Mansi L. Wechsler Adult Intelligence Scale performance. Cortical localization by fluorodeoxyglucose F 18-positron emission tomography. Archives of Neurology. 41: 1244-7. PMID 6333862 DOI: 10.1001/archneur.1984.04050230026012  1
1984 Keeler JR, Shults CW, Chase TN, Helke CJ. The ventral surface of the medulla in the rat: pharmacologic and autoradiographic localization of GABA-induced cardiovascular effects. Brain Research. 297: 217-24. PMID 6326937 DOI: 10.1016/0006-8993(84)90563-8  1
1984 Chronwall BM, Chase TN, O'Donohue TL. Coexistence of neuropeptide Y and somatostatin in rat and human cortical and rat hypothalamic neurons. Neuroscience Letters. 52: 213-7. PMID 6151631 DOI: 10.1016/0304-3940(84)90164-2  1
1984 Foster NL, Newman RP, LeWitt PA, Gillespie MM, Larsen TA, Chase TN. Peripheral beta-adrenergic blockade treatment of parkinsonian tremor. Annals of Neurology. 16: 505-8. PMID 6149724 DOI: 10.1002/ana.410160412  1
1984 Foster NL, Newman RP, LeWitt PA, Gillespie MM, Chase TN. Treatment of resting tremor by beta-adrenergic blockade. American Heart Journal. 108: 1173-7. PMID 6148881 DOI: 10.1016/0002-8703(84)90603-3  1
1984 O'Donohue TL, Massari VJ, Pazoles CJ, Chronwall BM, Shults CW, Quirion R, Chase TN, Moody TW. A role for bombesin in sensory processing in the spinal cord. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 4: 2956-62. PMID 6094746  1
1984 Knight M, Tamminga CA, Steardo L, Beck ME, Barone P, Chase TN. Cholecystokinin-octapeptide fragments: binding to brain cholecystokinin receptors. European Journal of Pharmacology. 105: 49-55. PMID 6092115 DOI: 10.1016/0014-2999(84)90647-2  1
1984 Burcher E, Shults CW, Buck SH, Chase TN, O'Donohue TL. Autoradiographic distribution of substance K binding sites in rat gastrointestinal tract: a comparison with substance P. European Journal of Pharmacology. 102: 561-2. PMID 6092101 DOI: 10.1016/0014-2999(84)90583-1  1
1984 Helke CJ, Shults CW, Chase TN, O'Donohue TL. Autoradiographic localization of substance P receptors in rat medulla: effect of vagotomy and nodose ganglionectomy. Neuroscience. 12: 215-23. PMID 6087197 DOI: 10.1016/0306-4522(84)90148-9  1
1984 Shults CW, Quirion R, Chronwall B, Chase TN, O'Donohue TL. A comparison of the anatomical distribution of substance P and substance P receptors in the rat central nervous system. Peptides. 5: 1097-128. PMID 6085163 DOI: 10.1016/0196-9781(84)90177-3  1
Show low-probability matches.